All News
Half of Subclinical Synovitis Patients May Remit
Ultrasound subclinical synovitis is found in a third of individuals at risk of rheumatoid arthritis (RA) patients; in half of these, subclinical synovitis resolves with a favorable outcome.
Read Article
Outcomes of Acute, Subacute and Persistent Low Back Pain
d
EurekAlert!
Low back pain is a major cause of disability around the globe, with more than 570 million people affected. In the United States alone, health care spending on low back pain was $134.5 billion between 1996 and 2016, and costs are increasing.
Read Article
Diet and Osteoarthritis Pain
d
MedPage Today
Knee osteoarthritis (OA) pain was worse with a pro-inflammatory diet, an observational study suggested.
Read Article
Metabolic Syndrome increases RA risk. UK Biobank (369,065) study saw 4901 incident RA (12 yrs F/U). Signif hi RA risk with MetS (HR 1.22), waist circumf (1.21), incr TG (1.12), decr HDL (1.31) & hyperglycemia (1.15) - all additive. https://t.co/jN15axxTmu https://t.co/DP5bFwOB3F
Dr. John Cush RheumNow ( View Tweet)
Greek study finds 251/1264 #RA pts (20%) had difficult to treat RA (D2T). D2T Predictors were Younger age, fibromyalgia, OA, no change in DAS28-ESR in 1st 6mos b/ts-DMARD Rx. Mental-/pain-/metabolic-Dz contributed to LT worsening https://t.co/QIsu6yIJHO https://t.co/NyKKlyOQi1
Dr. John Cush RheumNow ( View Tweet)
Study of 235 newly Dx #RA patients (157 females) found that 11 pts (5%) had carpal tunnel syndrom (CTS) at the time of initial RA diagnosis. Such pts were more likey to be older, female, CCP negative and have a longer Sx duration. https://t.co/Jb3hynyqGx https://t.co/EbTvHGq5Yk
Dr. John Cush RheumNow ( View Tweet)
16% of patients with nr-axSpA progressed to r-axSpA within 5 years. Male sex, fulfillment of the imaging arm of the ASAS criteria, and good response to nonsteroidal anti-inflammatory drugs were predictors of radiographic progression https://t.co/2qCynSGQjv https://t.co/eogKGacpqH
Dr. John Cush RheumNow ( View Tweet)
Dead Words Eulogy
This is a bonus lecture provided to RheumNow Live 2024 registrants, and being shared with our RheumNow audience. Today is the last day to register to attend virtually (or in person); go to https://t.co/fc9DGbVDJ5 for more information.
https://t.co/d4IbIbAIX8 https://t.co/egNtTNincb
Dr. John Cush RheumNow ( View Tweet)
Celebrities/famous folk who've had hip replacement: Steve Carrell Arnold Schwarzenegger, Michael Douglas, Billy Joel, Jane Fonda, Ray Charles, Eddie Van Halen, Bob Hope, Steve Perry,
Lionel Richie, Alec Baldwin & soon Paulina Porizkova https://t.co/z3v39gxAZa https://t.co/uqNJuPLUHL
Dr. John Cush RheumNow ( View Tweet)
No evidence of harm starting urate lowering Tx (ULT) during #gout attack. Metanalysis 6 RCTs (445 pts) w/ gout attacks given ULT vs PBO or delayed ULT. No differences in pain, time to resolve gout flare or risk of recurrent gout flare in 30d (RR 1.06) https://t.co/Spxoe3CI1q https://t.co/ECya8rvf1S
Dr. John Cush RheumNow ( View Tweet)
Microbiome study of 16 SLE pts (44 fecal samples) shows that blooms of Ruminococcus gnavus pathobiont was assoc w/ lupus flares and may be the drivers of clinical of relapsing lupus disease https://t.co/DIir59dkdM https://t.co/0p7Pat4gXS
Dr. John Cush RheumNow ( View Tweet)
Biden administration will re-negotiate top 10 Medicare costly drugs - this includes two of interest to rheumatologists
1. Stelara (ustekinumab) - avg Part D Rx cost = $119,951
2. Enbrel (etanercept) - avg Pt D Rx cost = $58,148
https://t.co/HuXmFodZfd https://t.co/BuGl34Zpv5 https://t.co/uniQoEywDB
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Safety Warning: denosumab now has a Boxed Warning for risk of severe hypocalcemia in CKD pts taking Prolia (usually seen 2-10 wks post injx). Pts may or may not be symptomatic. CKD pts should have Ca and Creatinine monitored. https://t.co/UMYxjWz9n4 https://t.co/AG5wzBrY1Y
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists and the Early Diagnosis of Spondyloarthritis
SPACE study of adults referred to rheumatology with less than 2 years of chronic back pain (CBP), shows that only one-third can be reliably diagnosed with axial spondyloarthritis (axSpA).
https://t.co/nUappTl0wG. https://t.co/oouir55CO6
Dr. John Cush RheumNow ( View Tweet)
Prevalence of Cardiovascular Disease in Rheumatoid Arthritis
A prospective study of the BioSTAR registry estimates the prevalence of cardiovascular disease in rheumatoid arthritis (RA) to be 4.6%.
https://t.co/NRn0DrYoBX https://t.co/qOoTmBNB1p
Dr. John Cush RheumNow ( View Tweet)
#RNL2024 @RheumNow SPA spectrum Q and A 🔥 - @lihi_eder 👏advocating for #POCUS #mskus and enthesitis - we agree @CrusSurc - confirming the concept of #pocus as an extension of the clinical exam and to be kept in the hands of the clinician - doesn't seem an area yet for AI 🤖
CRUS-SURC CrusSurc ( View Tweet)
Oh, snap! But this is true, a single course rituximab at baseline and none at 6 months (or anything else) as a comparator is just wild in a 12 month trial @EBRheum @RheumNow #RNL2024 https://t.co/wuIkuLzIpg
Richard Conway RichardPAConway ( View Tweet)
A picture paints a thousand words. One of the reasons why statistical significance is not the be all and end all. I would say severe DAH is the most likely scenario I would use PLEX, more so than severe renal disease. @EBRheum @RheumNow #RNL2024 https://t.co/GHg6t4OHxf
Richard Conway RichardPAConway ( View Tweet)
Rituximab is superior to cyclophosphamide in relapsing AAV. Provided you are relapsing after having cyclophosphamide as your first agent of course... @EBRheum @RheumNow #RNL2024 https://t.co/JfbcKH2zCG
Richard Conway RichardPAConway ( View Tweet)
Does adding NSAID to TNFi help prevent radiographic progression?
@LianneGensler
#RNL2024 @RheumNow
Adding Celecoxib to TNFi: numerically less progression, but not statistically significant https://t.co/rzuOL9q93x
Eric Dein ericdeinmd ( View Tweet)